University of Alabama at Birmingham

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Alabama at Birmingham sits in the top decile of US sponsors by registered trial count (#26 of 15,742 sponsors by registered trial count).

1,160 total trials 216 currently recruiting 723 completed early-phase tilt top decile by trial count

University of Alabama at Birmingham: 1,160 sponsored US clinical trials, 216 recruiting.

University of Alabama at Birmingham sponsors 1,160 registered US clinical trials on ClinicalTrials.gov, 216 of them currently recruiting, and 723 completed. 97 of these trials are in Phase 3-4 (later-stage) and 259 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 15 trials.

Top-decile sponsor footprint

University of Alabama at Birmingham ranks in the top decile of sponsors by registered trial count (#26 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 62/100

723 of 812 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,160 total, page 20 of 24

COMPLETED Phase 2

Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas

NCT01158651

COMPLETED Phase 2

Combined Behavioral and Drug Treatment of Overactive Bladder in Men

NCT01175382

TERMINATED Phase 4

Changes in Bone Turnover With Increased Incretin Hormone Exposure

NCT01374568

COMPLETED Phase 3

Calorie Restriction and Changes in Body Composition, Disease, Function, and Quality of Life in Older Adults

NCT00955903

COMPLETED Phase 4

Intranasal Oxytocin for the Treatment of Pain Associated With Interstitial Cystitis

NCT00919802

COMPLETED NA

Home-Based Automated Therapy of Arm Function After Stroke Via Tele-Rehabilitation

NCT01157195

COMPLETED NA

Longitudinal Study of Dental Implant Therapy in HIV Positive Patients

NCT01211288

COMPLETED NA

Comparison of Weight Management Programs Delivered in Large Versus Small Groups

NCT02088749

COMPLETED NA

Improving Care of Osteoporosis: Multi-Modal Intervention to Increase Testing and Treatment (ICOMMIITT)

NCT00788632

COMPLETED Phase 4

Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation

NCT01134731

TERMINATED NA

A Pilot Study of NSICU Assessment of Seizure Prophylaxis With Lacosamide

NCT01110187

COMPLETED NA

Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters

NCT01028014

TERMINATED

Prospective Study to Evaluate Outcomes From Transoral BOT Resection for OSAHS

NCT01107795

COMPLETED Phase 2

Nasal Potential Studies Utilizing Cystic Fibrosis Transmembrane Regulator (CFTR) Modulators

NCT01348204

COMPLETED

Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository

NCT01070121

COMPLETED

Study of Subthalamic Brain Stimulation in Parkinson Disease (PD)

NCT01113684

COMPLETED NA

IVR-Enhanced Care Transition Support for Complex Patients

NCT01135381

COMPLETED NA

Dietary Supplements and Aging Muscle

NCT01057082

COMPLETED

Predictors of Response to Fenofibrate

NCT01023750

COMPLETED

The Bone-Fat-Pancreas Axis in Children

NCT01041898

COMPLETED NA

Critical Periods of Exercise

NCT01041820

COMPLETED

Bad Genes or Genes Behaving Badly

NCT01041664

COMPLETED

Vascular Function, Insulin Sensitivity, and Vitamin D

NCT01041547

COMPLETED

Tissue Partitioning in Early Childhood

NCT01041794

COMPLETED NA

A Reduced Carbohydrate Diet Intervention for Polycystic Ovary Syndrome (PCOS)

NCT01028989

COMPLETED

Vitamin D, Insulin Sensitivity, and Vascular Associations in Adolescents

NCT01041365

TERMINATED NA

Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma

NCT01005875

COMPLETED

Voice and Swallowing Outcomes Following Revision Anterior Cervical Spine Surgery

NCT01017055

COMPLETED Phase 3

Using Virtual Reality to Train Children in Pedestrian Safety

NCT00850759

COMPLETED NA

Integrated Smoking Cessation Treatment for Low Income Community Corrections

NCT01257490

TERMINATED NA

Evaluation of Patients With Bulky GIST Using Sunitinib

NCT01054911

COMPLETED Phase 1

A Study of an Infectivity Enhanced Suicide Gene Expressing Adenovirus for Ovarian Cancer in Patients With Recurrent Ovarian and Other Selected Gynecologic Cancers

NCT00964756

COMPLETED NA

Chewing Gum for Weight Loss

NCT00971347

TERMINATED NA

Staples Versus Suture for Cesarean Wound Closure

NCT01008449

COMPLETED Phase 2

A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1

NCT00853580

COMPLETED NA

Chewing Gum Facilitates an Earlier Return to Bowel Function in Pediatric Scoliosis Patients: A Prospective Randomized Study

NCT02165436

COMPLETED Phase 2

Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)

NCT01204203

COMPLETED NA

Endoscopic Ultrasound (EUS) Guided-Celiac Plexus Neurolysis (CPN) in Unresectable Pancreatic Cancer

NCT00968175

COMPLETED

The Relative Prevalence and Severity of Autonomic Nervous System Dysfunction

NCT00919347

COMPLETED NA

Enhancing Physical Activity Adherence After Breast Cancer Diagnosis (BEAT Cancer II)

NCT00929617

COMPLETED Phase 1

Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer

NCT00856830

COMPLETED NA

Clinical Trial Evaluating the Optimal Technique for Chest Tube Removal

NCT00873587

COMPLETED Phase 4

Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in Healthy Women

NCT00869960

COMPLETED NA

Improving Osteoporosis Care in High-Risk Home Health Patients

NCT00679198

COMPLETED Phase 1

Resistance Training and Physical Functioning in Head and Neck Cancer Patients

NCT01332682

COMPLETED

TLR4 Polymorphisms and Risk of Skin Cancer

NCT03122366

COMPLETED Phase 4

The Bioequivalence of Atripla in an Oral Liquid Formulation Compared With the Tablet Formulation in Healthy Volunteers

NCT00862823

TERMINATED Phase 2

7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients

NCT00841035

COMPLETED NA

Effect of Valacyclovir in the Reduction of HSV-2 Recurrence and Shedding

NCT00803543

COMPLETED NA

Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment

NCT01897727

← Previous Page 20 of 24 Next →

Phase Distribution

PhaseTrial count
Phase 1 129
Phase 2 130
Phase 3 25
Phase 4 72

What is open in the University of Alabama at Birmingham pipeline

216 recruiting of 1,160 indexed (19% open); 723 completed (62%).

Phase mix: 97 late (III/IV) vs 259 early (I/II) (early-phase heavy).

Top condition: Obesity (15 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Alabama at Birmingham: open-pipeline peers nationwide

Peers matched on 1,160 registered trials and 19% open enrollment, not the therapeutic-area sidebar.

University of Alabama at Birmingham sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 15%16%17%18%19% Total trials Recruiting share University of Alabama at BirminghamNYU Langone HealthWake Forest University Health SciencesEmory UniversityNorthwestern UniversityUniversity of MinnesotaMclean HospitalChildren's Hospital Medical Center, CincinnatiArkansas Children's Hospital Research Institute
University of Alabama at Birmingham sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Alabama at Birmingham sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,160 trials (± recruiting share)

Sponsors near 19% open enrollment (± trial volume)

What to do with this University of Alabama at Birmingham page

1,160 registered trials is a research-attention snapshot, not an endorsement of University of Alabama at Birmingham or any single study.

  • 216 of University of Alabama at Birmingham's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition University of Alabama at Birmingham studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Alabama at Birmingham pipeline card: 1,160 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.